|
|
|
|
|
|
Sponsored by: |
International Extranodal Lymphoma Study Group (IELSG) |
Information provided by: | International Extranodal Lymphoma Study Group (IELSG) |
ClinicalTrials.gov Identifier: | NCT00210327 |
The primary objective of this study is to assess the antitumor activity (in terms of overall response rate - ORR - i.e. sum of complete and partial responses)of bortezomib in pretreated MALT lymphomas with one prior sistemic therapy regimen
Condition | Intervention | Phase |
Lymphoma, Mucosa-Associated Lymphoid Tissue |
Drug: Bortezomib (drug) |
Phase II |
MedlinePlus related topics: | Lymphoma |
ChemIDplus related topics: | Bortezomib |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Phase II Study of VELCADE in Patients With Extranodal Marginal Zone B-Cell Lymphoma of MALT-Type Pretreated With One Prior Systemic Therapy Regimen (X05142) |
Estimated Enrollment: | 33 |
Study Start Date: | July 2005 |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
for primary gastric localized H. pylori-positive disease at diagnosis:
Exclusion Criteria:
Contact: Cristina Morinini | +41 91 8119040 | ielsg@ticino.com |
Switzerland | |||||
Oncology Institute of Southern Switzerland (IOSI) | Recruiting | ||||
Bellinzona, Switzerland, 6500 | |||||
Contact: Cristina Morinini +41 91 8119040 ielsg@ticino.com | |||||
Principal Investigator: Emanuele Zucca, MD | |||||
Principal Investigator: Annarita Conconi, MD |
International Extranodal Lymphoma Study Group (IELSG) |
Study Chair: | Franco Cavalli, MD | International Extranodal Lymphoma Study Group |
Click here for more information about this study 
  |
Study ID Numbers: | IELSG25A |
First Received: | September 13, 2005 |
Last Updated: | September 13, 2005 |
ClinicalTrials.gov Identifier: | NCT00210327 |
Health Authority: | Switzerland: Swissmedic |
|
|
|